MedTrace Logo

Long-Term Non-Interventional Latanoprost Study

NCT01265719 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 175

Last updated 2021-02-03

Study results available
· View outcomes & findings →

Summary

This is a non-interventional, prospective, longitudinal cohort study. A total of 150 pediatric subjects with glaucoma or elevated intraocular pressure, including 75 latanoprost-treated subjects and 75 non-topical prostaglandin analogue treated subjects, will be enrolled from ophthalmic hospital clinics and academic ophthalmic centers. As a non-interventional study, the study subjects' continued use of latanoprost and assessments of ocular events will be obtained through the routine medical follow-up with treating ophthalmologists or other designated members of the medical care team.

Conditions

Interventions

OTHER

No intervention other than routine medical care

Subjects continuously treated with Latanoprost for at least one month Latanoprost treatment during the study period.

OTHER

No intervention other than routine medical care

Subjects not treated with any topical prostaglandin analogues or continuously treated with topical prostaglandin analogues for less than one month before the baseline examination, and unlikely to be treated with topical prostaglandin analogues during the study period.

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
1 Day
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2016-02-29
Completion
2016-02-29

Countries

  • Belgium
  • Colombia
  • Czechia
  • Denmark
  • France
  • Germany
  • Greece
  • Italy
  • Peru
  • Portugal
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01265719 on ClinicalTrials.gov